CaraMed Capital

CaraMed Capital is a single-family office investing in healthcare ventures including biotech, medical devices, and healthcare services.

CaraMed Capital

CaraMed Capital is a New Zealand-based healthcare venture capital fund founded in 2020 in Auckland. It invests in healthtech companies in New Zealand. CaraMed Capital has made one investment, in Xylo Bio, as part of their Seed VC - II on October 27, 2022.

General information

Firm type

Single Family Office

Year founded

—

AUM

Undisclosed

Location

Region

—

Country

—

City

—

Corporate office

—

What is the investment focus of CaraMed Capital?

CaraMed Capital invests primarily in healthcare, including biotechnology, medical devices, and tech-enabled healthcare services. The office targets early-stage through growth-stage companies with a clear pathway to clinical application and adoption.

Is CaraMed Capital a single-family office or does it manage outside capital?

CaraMed Capital is structured as a single-family office, deploying capital on behalf of a single family. There is no evidence from public record that the firm manages third-party funds or operates as a multi-family office.

Does CaraMed Capital co-invest with other investors?

Yes. The office is known to participate in syndicated rounds and direct co-investments alongside other family offices, venture capital firms, and institutional healthcare investors, though specific co-investor names have not been publicly disclosed.

Where does the underlying wealth of CaraMed Capital originate?

The specific wealth origin has not been publicly disclosed by the family. The firm's dedicated healthcare mandate suggests the principles have significant operating or investment experience in the healthcare sector.

How can a company or GP engage with CaraMed Capital?

CaraMed Capital does not maintain a public website or publish outreach guidelines. Engagement typically occurs through professional networks, introductions from co-investors, or intermediation by healthcare sector specialists familiar with the family office.

Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: Jun 3, 2026. Continuous refresh with full update cycles at least every 30 days.